| Document |
Document Title |
|
WO/2011/062078A1 |
Disclosed is a dopa oxidase activity inhibitor which contains a compound represented by general formula (1) as an active ingredient. Also disclosed is a skin whitening agent which contains the compound as an active ingredient. (In the fo...
|
|
WO/2011/029547A2 |
The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, methods of preparing such compounds, pharmaceutical compositions comprising them, combinations and therapeutic uses th...
|
|
WO/2011/011984A1 |
Sterol derivatives with structural formula I or II are disclosed, wherein R is defined as the description of the invention. Their synthesizing methods and anti-tumor use are also disclosed. Especially, the compound of formula I, in which...
|
|
WO/2010/147947A2 |
The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, or isomers of said compounds), having the general structure: Formula (I) wherein L, R1, R2, R3, R4, R5...
|
|
WO/2010/133687A1 |
The present invention relates to a compound with the following formula (I), or to a pharmaceutically acceptable salt thereof, as well as to pharmaceutical compositions including same and to the use thereof as a drug, in particular for tr...
|
|
WO/2010/126953A1 |
New chemical entities which comprise corticosteroids and phosphorylated β- agonists for use in therapy and compositions comprising and processes for preparing the same are provided.
|
|
WO/2010/122096A1 |
The present invention relates to a process for obtaining compounds of formula (I) and (V), wherein R1 is C1-C6 alkyl; and R2 is OR3, OC(=O)R4 or O-(HPG), wherein R3 is H, C1-C6 alkyl or C6-C14 aryl; R4 is H or C1-C6 alkyl; and HPG is a h...
|
|
WO/2010/114473A1 |
The present invention provides compounds of formula (I) wherein n, p, R1,R2,X1,X2,X3,X4,X5,R3a,R3b,R4,R5,R6, are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use ...
|
|
WO/2010/114472A1 |
The invention provides a pharmaceutical product comprising, in combination, (1 ) (1 R,3aS,3bS,1 OaR, 10bS, 11 S,12aS)1-{[(cyanomethyl)sulfanyl]carbonyl}-7-(4-fluorophenyl
)- 1 1 -hydroxy-10a,12a-dimethyl-1,2,3,3a,3b, 4,5,7,10,10a, 10b, 1...
|
|
WO/2010/114476A1 |
The present invention provides named compounds of formula (I), and pharmaceutical compositions containing them and their use in therapy.
|
|
WO/2010/114471A1 |
The present invention provides compounds of formula (I) wherein n, R1, R2, X1, X2, X3, X4, X5, R3a, R3b, R4, R5 and R6 are defined in the specification, a process for their preparation, pharmaceutical compositions containing them and the...
|
|
WO/2010/104187A1 |
A steroid compound represented by formula (1). [In formula (1), R1 is H or a group selected from CH3, C2H5, C3H7, and CH(CH3)2, R2 is a group selected from NH2, NHAc, and OCOR1, and R3 is a group selected from CH3, COOCH3, and CH2OCOR1.]
|
|
WO/2009/108118A9 |
The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
|
|
WO/2010/012567A1 |
The invention relates to nitrooxy derivatives of fluocinolone acetonide, triamcinolone acetonide, betamethasone and beclomethasone, methods for their preparation, pharmaceutical compositions containing these compounds, and methods of usi...
|
|
WO/2010/009828A1 |
The present invention is directed to novel pyrazolo-estrien and triazolo-estrien-derivatives, pharmaceutical compositions containing them and their use in the treatment or prevention of disorders and diseases mediated by an estrogen rece...
|
|
WO/2009/153800A1 |
A novel, commercially viable process for the extraction of high purity (>70%), bioactive furostanolic saponins including protodioscin (>30%), from the seeds of fenugreek (Trigonella foenumgraecum) comprising essentially the steps of powd...
|
|
WO/2009/152171A1 |
New chemical entities which comprise corticosteroids and phosphorylated β-agonists for use in therapy and compositions comprising and processes for preparing the same.
|
|
WO/2009/149392A1 |
The invention relates to processes for preparing 17-alkynyl-7-hydroxy- steroids, such as 17-Ethynyl-10R13S-dimethyl 2,3,4,7,8R,9S, 10,11,12,13,14S,15,16,17-hexadecahydro-1 H-cyclopenta[a]phenanthrene- 3R,7R,17S-triol (also referred to as...
|
|
WO/2009/146218A2 |
This invention provides novel compounds comprising the following anti-inflammatory pharmacore Formula (I): wherein X, R1 and R2 are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprisin...
|
|
WO/2009/136629A1 |
Disclosed is a method for the screening of a compound having an activity to selectively modulate an androgen receptor. The method comprises the steps of: contacting a substance to be tested with a prostate cancer cell and measuring the ...
|
|
WO/2009/133401A1 |
The invention provides a synthetic route from sarsasapogenin to timosaponin BII a related compounds. A diketone intermediate is provided, which can advantageously used for in situ assembly of complex sugar moieties of the desired glycone...
|
|
WO/2009/132478A1 |
The invention provides a synthetic route from sarsasapogenin to timosaponin BII and related compounds.A diketone intermediate is provided, which can advantageously be used for in situ assembly of complex sugar moieties of the desired gly...
|
|
WO/2009/124460A1 |
The invention discloses Tripterygium wilfordii diterpene lactone derivatives represented by formula (1), their optical isomers and pharmaceutically acceptable salts and hydrates. The invention also provides pharmaceutical compositions an...
|
|
WO/2009/122435A2 |
The present invention relates to preparation and biological evaluation of 3-acetoxy-17- acetamido-16-formyl-androst-5,17-diene (4) and 3-acetoxy2'-chloro-5-androsteno [17,16- b]pyridine (5) as gastric proton pump inhibitor and their comp...
|
|
WO/2009/120678A2 |
Steroids are well known, medicinal relevant, chemical entities. There are numerous steroids which have fully or partially reduced 1A' rings. These fully or partially reduced 1A' rings have been reduced in the past through Birch and other...
|
|
WO/2009/117120A1 |
The present invention provides a purification method for air sensitive steroids, by reacting an amino acid or an analogue thereof with the 21-aldehyde oxidation product of such air sensitive steroids to form an adduct that is separated f...
|
|
WO/2009/112557A2 |
A stereoselective and enrichment process for the preparation of ciclesonide is described.
|
|
WO/2009/096445A1 |
Disclosed are a neural stem cell propagation accelerator which contains a compound produced by Penicillium sp. strain CND1007 (FERM BP-10917) or a pharmacologically acceptable salt thereof, a novel compound produced by Penicillium sp. st...
|
|
WO/2009/085880A2 |
The present invention provides compounds of Formula (VII) and 11-keto analogs thereof, and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, and isomers of said compounds and said 11-keto analogs, having the gener...
|
|
WO/2009/082342A1 |
The present invention provides compounds of formula (I) wherein n, p, R1, R2, X1, X2 , X3, R3a, R3b, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and thei...
|
|
WO/2009/069032A2 |
This invention relates to novel glucocorticoid receptor agonists of formula (I) and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical compositions containing these compounds, to th...
|
|
WO/2009/044200A1 |
The present invention provides compounds of formula (I) wherein n, p, R1, R2, X1, X2, X3, X4, X5, R3a, R3b, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them a...
|
|
WO/2009/004638A1 |
The present invention provides a novel steroidal glycoside of formula I for management of rheumatic and inflammatory disease conditions. In addition, the present invention also provides a process for preparation of steroidal glycoside fr...
|
|
WO/2008/136863A2 |
As described herein, the present invention provides methods for preparing compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the s...
|
|
WO/2008/115069A2 |
The present invention relates to certain unsaturated fatty acid derivatives of therapeutically active glucocorticoidesfatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents and pharmaceutical formulations contai...
|
|
WO/2008/101308A1 |
The present invention relates to a process for producing 17-N-substituted-carbamoyl-4-aza-androst-1-en-3-ones of formula (1) , including Finasteride and Dutasteride.
|
|
WO/2008/062450A2 |
The present invention discloses a novel crystalline forms of Ciclesonide of formula (I) and the process for preparation thereof. The present invention also provides a process for preparing amorphous form of Ciclesonide.
|
|
WO/2008/037226A2 |
The invention relates to a method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, wherein the water-insoluble terpenoid having a free carboxylic, hydroxy or amino functional group is der...
|
|
WO/2008/035066A2 |
Improved process for the synthesis of ciclesonide and its crystal form.
|
|
WO/2008/026300A1 |
The object is to provide a novel therapeutic agent for malignant tumor. Disclosed is a therapeutic agent for malignant tumor or an apoptosis inducer which comprises a compound selected from epoxyazadiradione, gedunin, 17-epi-17-hydroxyaz...
|
|
WO2007127012B1 |
The present invention relates to novel enfumafungin derivatives of formula I and pharmaceutically acceptable salts thereof, their synthesis, and their use as inhibitors of (l,3)-ß-D-glucan synthase. The present compounds and pharmaceuti...
|
|
WO/2008/015696A2 |
A process for enantiomeric enriching the (R)-Ciclesonide is enclosed. The process comprises providing mixture of (R)-Ciclesonide: (S)-Ciclesonide to chromatography using a chiral stationary phase.
|
|
WO/2008/012833A1 |
The present invention provides an improved process for the preparation of 16-dehydropregenolone acetate [16-DPA], wherein pseudodiosgenin diacetate (PDA) is oxidized to diosone by catalytic amount of KMnO4 in the presence of a co oxidant...
|
|
WO/2007/144674A1 |
The present invention relates to a new industrial process for the synthesis of solvate- free 17α-acetoxy-11β-[4-(N,N-dimethyl-amino)-phenyl]-19-norpreg
na-4,9-diene-3,20-dione [CDB -2914] of formula (I) which is a strong antiprogestoge...
|
|
WO/2007/141390A1 |
The invention relates to conipouns derived from betulin, and to the use thereof as antiviral agents in applications of pharmaceutical industry, particularly as agents against alphaviruses.
|
|
WO/2007/141392A2 |
The invention relates to compositions of cosmetic and pharmaceutical industries comprising betulonic acid for humans and animals, and further, to the use of betulonic acid in compositions of cosmetic and pharmaceutical industries. The in...
|
|
WO/2007/141391A1 |
The invention relates to betulin derivatives, and to the use thereof as agents against protozoa of the genus Leishmania and against leishmaniasis in applications of pharmaceutical industry.
|
|
WO/2007/141389A1 |
The invention relates to compouns derived from betulin, and to the use thereof as antibacterial agents in pharmaceutical and cosmetic applications.
|
|
WO2007054974B1 |
A process for the preparation of Pregna-1, 4-diene - 3,20-dione-16,17-acetal-21 esters of Formula (I) by a green process chemistry using a combination of an ionic liquid, organic solvent optionally in the presence of an inorganic nitrite...
|
|
WO/2007/126900A2 |
The present invention relates to novel enfumafungin derivatives of Formula IV-IA and pharmaceutically acceptable salts thereof, their synthesis, and their use as inhibitorspf(r,3)-β-D-glucan synthase. The present compounds and pharmaceu...
|
